These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21951832)

  • 1. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.
    Al Sifri S; Basiounny A; Echtay A; Al Omari M; Harman-Boehm I; Kaddaha G; Al Tayeb K; Mahfouz AS; Al Elq A; Radican L; Ozesen C; Katzeff HL; Musser BJ; Suryawanshi S; Girman CJ; Davies MJ; Engel SS;
    Int J Clin Pract; 2011 Nov; 65(11):1132-40. PubMed ID: 21951832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
    Hassanein M; Echtay A; Hassoun A; Alarouj M; Afandi B; Poladian R; Bennakhi A; Nazar M; Bergmans P; Keim S; Hamilton G; Azar ST
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28851109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
    Azar ST; Echtay A; Wan Bebakar WM; Al Araj S; Berrah A; Omar M; Mutha A; Tornøe K; Kaltoft MS; Shehadeh N
    Diabetes Obes Metab; 2016 Oct; 18(10):1025-33. PubMed ID: 27376711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
    Wan Seman WJ; Kori N; Rajoo S; Othman H; Mohd Noor N; Wahab NA; Sukor N; Mustafa N; Kamaruddin NA
    Diabetes Obes Metab; 2016 Jun; 18(6):628-32. PubMed ID: 26889911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
    Devendra D; Gohel B; Bravis V; Hui E; Salih S; Mehar S; Hassanein M
    Int J Clin Pract; 2009 Oct; 63(10):1446-50. PubMed ID: 19678856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.
    Aravind SR; Al Tayeb K; Ismail SB; Shehadeh N; Kaddaha G; Liu R; Balshaw R; Lesnikova N; Heisel O; Girman CJ; Musser BJ; Davies MJ; Katzeff HL; Engel SS; Radican L;
    Curr Med Res Opin; 2011 Jun; 27(6):1237-42. PubMed ID: 21506631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
    Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
    Brady EM; Davies MJ; Gray LJ; Saeed MA; Smith D; Hanif W; Khunti K
    Diabetes Obes Metab; 2014 Jun; 16(6):527-36. PubMed ID: 24373063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attitude and safety of patients with diabetes observing the Ramadan fast.
    Ba-Essa EM; Hassanein M; Abdulrhman S; Alkhalifa M; Alsafar Z
    Diabetes Res Clin Pract; 2019 Jun; 152():177-182. PubMed ID: 30946851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.
    Mahar SA; Hasan MI; Khan MI; Fawwad A; Hussain S; Maheshwary N; Kumar K; Siddiqi A; Khan MA
    J Pak Med Assoc; 2014 Nov; 64(11):1297-302. PubMed ID: 25831650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
    Al-Arouj M; Hassoun AA; Medlej R; Pathan MF; Shaltout I; Chawla MS; Hristoskova S; Ditommaso S; Kadwa MY
    Int J Clin Pract; 2013 Oct; 67(10):957-63. PubMed ID: 24001317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
    Anwar A; Azmi KN; Hamidon BB; Khalid BA
    Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitigation of hypoglycemia during Ramadan using the flash glucose monitoring system following dose adjustment of insulin and sulphonylurea in patients taking multiple glucose-lowering therapies (The PROFAST-IT Study).
    Elhadd T; Bashir M; Baager KA; Ali HA; Almohannadi DHS; Dabbous Z; Malik RA; Abou-Samra AB;
    Diabetes Res Clin Pract; 2021 Feb; 172():108589. PubMed ID: 33316309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
    Takihata M; Nakamura A; Tajima K; Inazumi T; Komatsu Y; Tamura H; Yamazaki S; Kondo Y; Yamada M; Kimura M; Terauchi Y
    Diabetes Obes Metab; 2013 May; 15(5):455-62. PubMed ID: 23279373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan.
    Zargar A; Basit A; Mahtab H
    J Indian Med Assoc; 2005 Aug; 103(8):444-6. PubMed ID: 16363203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
    Mafauzy M
    Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.